Back to Rankings

BDMD

Baird Medical InvestmentF
Nasdaq / Health Care Equipment & Services
Last Price
At close
2026-06-03
View Chart
Documents
1
Stored
Transcripts
0
Recent loaded
Latest report
2026-04-29
Investor release

Document history

Earnings documents stored for BDMD.

1 shown
Investor releaseQuarter not tagged2026-04-29

Baird Medical Reports Full Year 2025 Financial Results and Provides Corporate Update

PR Newswire

Full year 2025 revenue of $22.5 million, impacted by policy-driven slowdown in Mainland China Advancing global expansion with appointment of seasoned commercial leader, Mark Saxton, as CEO of Baird Medical U.S. to lead commercial ramp in the United States NEW YORK, April 29, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced its financial results for the full year ended December 31, 2025 and provided an update on key strategic and operational initiatives. "2025 was an important period in Baird's evolution as we began executing on our strategy to become a global, innovation-driven med tech organization," said Mrs. Haimei Wu, Chairman and Chief Executive Officer of Baird Medical. "The commercial environment in Mainland China was particularly challenging in light of recent policy changes, which has made our efforts to broaden the Company's geographic footprint of great importance. To that end, we reached an important milestone in the fourth quarter with the appointment of Mark Saxton as the CEO of Baird U.S. to lead our commercial ramp in this key market. Mark has built a sterling reputation over the last 25 years at companies including NeuroPace, Covidien and Smith + Nephew, launching a broad range of innovative technology solutions and growing them into market leaders. We have great confidence in the potential of our technology to thrive in the U.S. under Mark's leadership." "Our Microwave Ablation (MWA) technology offers patients a truly minimally invasive alternative that delivers excellent patient outcomes and reduces the uncertainty associated with watchful waiting. My early conversations with U.S. surgeons have been deeply encouraging and have only strengthened my conviction that there is a real, unmet need for novel solutions like MWA to address the needs of these patients," said Mark Saxton, Chief Executive Officer of Baird Medical U.S. "In 2026, we are laying the commercial foundation for sustainable long-term growth in the U.S., building the team, infrastructure, and market awareness that this technology deserves. In parallel, Baird is investing in the further advancement of our MWA platform, with the goal of expanding our portfolio and broadening the addressable market over time. We look forward to sh...

As of 2026-05-18 • Updated weeklySource: Earnings sourceIngestion runbook